Free Shipment Protection

2 Day USPS Express Shipping

Secure Checkout

Third-Party Tested

IN STOCK

IN STOCK

Click for COA

Tap for COA

GLP-2 (TR)

GLP-2 (TR)

A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.

A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.

Dosage

Strength

30 MG

$249.99

Stock & Save

1 unit

$249.99

STARTER

1 unit

$249.99

STARTER

3+ units

4% OFF

MOST POPULAR

3+ units

4% OFF

MOST POPULAR

5+ units

7% OFF

BEST SAVINGS

5+ units

7% OFF

BEST SAVINGS

10+ units

40% OFF

WHOLESALE

10+ units

40% OFF

WHOLESALE

1

1

Add to Cart - $249.99

Add to Cart - $249.99

Subscribe & Save Up to 10%

Subscribe & Save Up to 10%

DISCLAIMER: This product is intended for research use only (RUO). Not for human or animal consumption. Purchasers must be at least 21 years of age.

Free Shipment Protection

USPS Express Shipping

Secure Checkout

Third-Party Tested

ABOUT THIS COMPOUND

GLP-3 RT is the research name for retatrutide. It acts on three receptors at once: GLP-1, GIP, and glucagon. Research has examined how it affects metabolism, energy use, and blood sugar in study models. Most similar compounds hit only two receptors. The third target is what sets this one apart.

Triple GLP-1/GIP/glucagon receptor agonist peptide (LY3437943)

FORMULA

C₂₂₁H₃₄₂N₄₆O₆₈

FORM

Lyophilized powder

MOLECULAR WEIGHT

4731.32 g/mol

CAS / ID

LY3437943 (CAS 2381089-83-2)

LAB RESULTS

Verify at Freedom Diagnostics

TEST

TEST

Purity

Purity

Identity

Identity

Endotoxin (USP <85>)

Endotoxin (USP <85>)

Frequency

Frequency

RESULT

RESULT

99.62%

99.62%

10.44 mg

10.44 mg

NMT 0.05 EU / ml

NMT 0.05 EU / ml

230V / 460V

230V / 460V

STATUS

STATUS

PASS

Pass

PASS

Pass

PASS

Pass

PASS

Pass

Product Care

GLP-2 Storage & Handling

Review recommended storage conditions and handling practices designed to help maintain product integrity.

Review recommended storage conditions and handling practices designed to help maintain product integrity.

Recommended Storage

Recommended Storage

For storage periods of up to three months, keep the lyophilized powder at room temperature in a cool, dry, and dark environment. For extended storage, place the sealed vial in a laboratory freezer at −4°F (−20°C). Minimize exposure to light, moisture, and heat, and avoid unnecessary freeze–thaw cycles.

For storage periods of up to three months, keep the lyophilized powder at room temperature in a cool, dry, and dark environment. For extended storage, place the sealed vial in a laboratory freezer at −4°F (−20°C). Minimize exposure to light, moisture, and heat, and avoid unnecessary freeze–thaw cycles.

Expected Shelf Life

Expected Shelf Life

When kept frozen in its original sealed vial, the manufacturer indicates that the lyophilized powder may remain stable for approximately 12–24 months. Release testing confirms the product’s identity, purity, content, and contaminant results at the time of testing; it should not be interpreted as an independent determination of shelf life.

When kept frozen in its original sealed vial, the manufacturer indicates that the lyophilized powder may remain stable for approximately 12–24 months. Release testing confirms the product’s identity, purity, content, and contaminant results at the time of testing; it should not be interpreted as an independent determination of shelf life.

Peer-reviewed research

PubMed Research

Explore the peer-reviewed studies behind the compounds in our catalog.

Explore the peer-reviewed studies behind the compounds in our catalog.

Jastreboff AM (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial N Engl J Med.

PMID: 34267654 →

PMID: 34267654

Rosenstock J (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Lancet.

PMID: 16099219 →

PMID: 16099219

Sanyal AJ (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nat Med.

PMID: 31158953 →

PMID: 31158953

Coskun T (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metab.

PMID: 15580368 →

PMID: 15580368

Common Questions

Understanding GLP-2 (TR)

Find answers about research specifications, quality testing, storage, documentation, and ordering.

Find answers about research specifications, quality testing, storage, documentation, and ordering.

1. What is GLP-3 (RT)?

GLP-3 (RT) is Open Science’s product name for retatrutide, also identified in published literature as LY3437943. This synthetic 39-amino-acid peptide is designed to activate the GIP, GLP-1, and glucagon receptors. It is supplied as a lyophilized powder exclusively for laboratory research and is not intended for human or animal use.

2. What is the molecular weight and formula of GLP-3 (RT)?

The sodium salt of retatrutide has a molecular weight of approximately 4,731 g/mol and a molecular formula of C₂₂₁H₃₄₂N₄₆O₆₈. Its structure includes a C20 fatty diacid component attached at lysine-20 through a linker.

3. How is GLP-3 (RT) different from tirzepatide and semaglutide?

The primary distinction is the number of receptor pathways studied. Semaglutide targets the GLP-1 receptor, while tirzepatide targets both the GIP and GLP-1 receptors. Retatrutide is studied as a triple agonist because it also targets the glucagon receptor. Comparative research involving these compounds remains ongoing.

4. How is each batch of GLP-3 (RT) evaluated?

Each batch undergoes independent laboratory analysis before release. Testing includes peptide identity, HPLC purity, and bacterial endotoxins. The tests performed and their corresponding results are documented on the batch-specific Certificate of Analysis available through our product page.

5. What purity standard does Open Science use for GLP-3 (RT)?

Open Science requires a minimum HPLC purity result of 99% for GLP-3 (RT). Because results can vary slightly between production lots, customers should consult the Certificate of Analysis for the exact purity reported for their batch.

6. How should lyophilized GLP-3 (RT) be stored?

Keep the sealed vial protected from light, moisture, and heat. For extended storage, the lyophilized material should be maintained at −4°F (−20°C) in a laboratory freezer. Avoid unnecessary freeze–thaw cycles, which may affect peptide integrity. The manufacturer indicates a frozen storage period of approximately 12–24 months for sealed material; Open Science release testing does not independently determine shelf life.

7. Where can I review published research on retatrutide?

Peer-reviewed publications can be found through PubMed by searching for “retatrutide” or its development code, “LY3437943.” Relevant literature includes receptor-characterization research by Coskun and colleagues, phase 2 studies led by Jastreboff and Rosenstock, and a phase 2a study led by Sanyal. Links to selected publications are available in the research section above.

1. What is GLP-3 (RT)?

GLP-3 (RT) is Open Science’s product name for retatrutide, also identified in published literature as LY3437943. This synthetic 39-amino-acid peptide is designed to activate the GIP, GLP-1, and glucagon receptors. It is supplied as a lyophilized powder exclusively for laboratory research and is not intended for human or animal use.

2. What is its molecular profile?

The sodium salt of retatrutide has a molecular weight of approximately 4,731 g/mol and a molecular formula of C₂₂₁H₃₄₂N₄₆O₆₈. Its structure includes a C20 fatty diacid component attached at lysine-20 through a linker.

3. How does GLP-3 (RT) differ?

The primary distinction is the number of receptor pathways studied. Semaglutide targets the GLP-1 receptor, while tirzepatide targets both the GIP and GLP-1 receptors. Retatrutide is studied as a triple agonist because it also targets the glucagon receptor. Comparative research involving these compounds remains ongoing.

4. How is each batch tested?

Each batch undergoes independent laboratory analysis before release. Testing includes peptide identity, HPLC purity, and bacterial endotoxins. The tests performed and their corresponding results are documented on the batch-specific Certificate of Analysis available through our product page.

5. What is its purity standard?

Open Science requires a minimum HPLC purity result of 99% for GLP-3 (RT). Because results can vary slightly between production lots, customers should consult the Certificate of Analysis for the exact purity reported for their batch.

6. How should GLP-3 (RT) be stored?

Keep the sealed vial protected from light, moisture, and heat. For extended storage, the lyophilized material should be maintained at −4°F (−20°C) in a laboratory freezer. Avoid unnecessary freeze–thaw cycles, which may affect peptide integrity. The manufacturer indicates a frozen storage period of approximately 12–24 months for sealed material; Open Science release testing does not independently determine shelf life.

7. Where can I find published research?

Peer-reviewed publications can be found through PubMed by searching for “retatrutide” or its development code, “LY3437943.” Relevant literature includes receptor-characterization research by Coskun and colleagues, phase 2 studies led by Jastreboff and Rosenstock, and a phase 2a study led by Sanyal. Links to selected publications are available in the research section above.

Commonly Selected

Frequently Bought Together

Frequently
Bought Together

Commonly selected by researchers exploring metabolic pathways from multiple angles.

Commonly selected by researchers exploring metabolic pathways from multiple angles.

IN STOCK

Triple-Action Metabolic Compound
Retatrutide

A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research.

30mg

View

Add to Cart

$199.99

IN STOCK

Triple-Action Metabolic Compound
Retatrutide

A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research.

30mg

View

Add to Cart

$199.99

IN STOCK

Metabolic Compound
Tirzepatide

A 39-residue synthetic linear peptide that acts as a dual agonist at both the GIP and GLP-1 receptors. A C20 fatty diacid chain at Lys-20 drives albumin binding for a once-weekly circulation profile.

60mg

View

Add to Cart

$109.99

IN STOCK

Metabolic Compound
Tirzepatide

A 39-residue synthetic linear peptide that acts as a dual agonist at both the GIP and GLP-1 receptors. A C20 fatty diacid chain at Lys-20 drives albumin binding for a once-weekly circulation profile.

60mg

View

Add to Cart

$109.99

IN STOCK

Metabolic Compound
Lipo-C

A long-acting GLP-1 receptor agonist: a 31-residue analog of human GLP-1 (~94% sequence homology) carrying a C18 fatty diacid chain via a linker that drives reversible albumin binding for extended circulation.

10mg

View

Add to Cart

$49.99

IN STOCK

Metabolic Compound
Lipo-C

A long-acting GLP-1 receptor agonist: a 31-residue analog of human GLP-1 (~94% sequence homology) carrying a C18 fatty diacid chain via a linker that drives reversible albumin binding for extended circulation.

10mg

View

Add to Cart

$49.99

Important Research Notice

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.


All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.


By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.


All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.


By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

  • All orders dispatched within 24hrs
  • 99%+ HPLC Purity
  • Third-Party Tested

Open Science

Research should be open to scrutiny. Independently tested compounds with clear, batch-specific Certificates of Analysis.

Resources

Research Library

Soon

COA Library

Soon

Support

Returns & Refunds
Shipping Information
Contact Us
© 2026 Open Science. All rights reserved.

FDA Disclaimer

Statements regarding our products have not been evaluated by the United States Food and Drug Administration (FDA). The effectiveness of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. The information presented on this website is not a substitute for information provided by a qualified healthcare professional. Consult an authorized healthcare professional regarding any possible interaction or complication before using any product. This notice is required under the Federal Food, Drug, and Cosmetic Act.

Open Science

Research should be open to scrutiny. Independently tested compounds with clear, batch-specific Certificates of Analysis.

Resources

Research Library

Soon

COA Library

Soon

Support

Returns & Refunds
Shipping Information
Contact Us
© 2026 Open Science. All rights reserved.

FDA Disclaimer

Statements regarding our products have not been evaluated by the United States Food and Drug Administration (FDA). The effectiveness of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. The information presented on this website is not a substitute for information provided by a qualified healthcare professional. Consult an authorized healthcare professional regarding any possible interaction or complication before using any product. This notice is required under the Federal Food, Drug, and Cosmetic Act.

Open Science

Research should be open to scrutiny. Independently tested compounds with clear, batch-specific Certificates of Analysis.

Resources

Research Library

Soon

COA Library

Soon

Support

Returns & Refunds
Shipping Information
Contact Us
© 2026 Open Science. All rights reserved.

FDA Disclaimer

Statements regarding our products have not been evaluated by the United States Food and Drug Administration (FDA). The effectiveness of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. The information presented on this website is not a substitute for information provided by a qualified healthcare professional. Consult an authorized healthcare professional regarding any possible interaction or complication before using any product. This notice is required under the Federal Food, Drug, and Cosmetic Act.